Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial.

Abstract

PURPOSE To establish the feasibility and tolerability of gefitinib (ZD1839, Iressa) with radiation (RT) or concurrent chemoradiation (CRT) with cisplatin (CDDP) in patients with advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS In this multicenter Phase I study, 5 patients with unresectable NSCLC received 250 mg gefitinib daily starting 1… (More)
DOI: 10.1016/j.ijrobp.2010.01.048

Topics

Cite this paper

@article{Rothschild2011GefitinibIC, title={Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial.}, author={Sacha Rothschild and Stephan Emanuel Bucher and Jacques Bernier and Daniel M. Aebersold and Aberrahim Zouhair and Gerhard Ries and Norbert Lombrieser and Thomas Lippuner and Urs Martin L{\"u}tolf and Christoph Glanzmann and Ilja Frank Ciernik}, journal={International journal of radiation oncology, biology, physics}, year={2011}, volume={80 1}, pages={126-32} }